Overview

Single Dose Preoperative Gabapentin Use in Minimally Invasive Hysterectomy for Acute Pain Management

Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
0
Participant gender:
Female
Summary
The purpose of the investigators' study is to assess the efficacy of a single dose of preoperative gabapentin within an enhanced recovery after surgery protocol in acute postoperative pain reduction for women undergoing a minimally invasive hysterectomy. Participants who consent to participate will be randomized to either a control group without gabapentin or to a study arm and receive gabapentin 600 mg prior to their planned surgery. The investigators will collect data on postoperative narcotic use, subjective pain as rated by a numeric pain scale, in addition to any adverse effects of single dose gabapentin use.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Christiana Care Health Services
Treatments:
Acetaminophen
Celecoxib
Gabapentin
gamma-Aminobutyric Acid
Criteria
Inclusion Criteria:

- undergoing a minimally invasive hysterectomy with surgeons operating within the
Christiana Care Health System at the Newark location only.

- at least 18 years of age

- able to swallow tablets or capsules

Exclusion Criteria:

- liver failure

- renal failure

- prior gastric bypass

- gastroparesis

- recent or current regular gabapentin use

- hypersensitivity to gabapentin, acetominophen, or celecoxib

- procedure is converted to laparotomy for any indication. (Mini-laparotomy for specimen
removal alone will not be excluded.)